会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 16. 发明申请
    • PROCESS FOR THE PREPARATION OF HINDERED PHOSPHITES
    • 制备有争议的磷酸盐的方法
    • WO02014335A1
    • 2002-02-21
    • PCT/US2001/020351
    • 2001-06-27
    • C07F9/6574
    • C07F9/65746C07F9/65742
    • A process to produce organic phosphites from the group consisting of formula (I), wherein each R , R , and R is independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, t-amyl, t-hexyl, cyclohexyl, cumyl, t-pentyl, and t-octyl; and wherein each R , R , and R is independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, t-amyl, t-hexyl, cyclohexyl, cumyl, t-pentyl, and t-octyl and each R and R is independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, t-amyl, t-hexyl, cyclohexyl, cumyl, t-pentyl, and t-octyl using a metal phenolate.
    • 一种从式(I)组成的组中生产有机亚磷酸酯的方法,其中每个R 1,R 2和R 3独立地选自氢,甲基,乙基,正丙基 异丙基,正丁基,叔丁基,叔戊基,叔己基,环己基,枯基,叔戊基和叔辛基; 并且其中每个R 1,R 2和R 3独立地选自氢,甲基,乙基,正丙基,异丙基,正丁基,叔丁基,叔丁基, 戊基,叔己基,环己基,枯基,叔戊基和叔辛基,每个R 4和R 5独立地选自氢,甲基,乙基,正丙基,异丙基 ,正丁基,叔丁基,叔戊基,叔己基,环己基,枯基,叔戊基和叔辛基。
    • 17. 发明申请
    • NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS
    • 含磷化合物的新产品
    • WO9945016A9
    • 2000-03-02
    • PCT/US9904908
    • 1999-03-05
    • METABASIS THERAPEUTICS INC
    • ERION MARK DREDDY K RAJAROBINSON EDWARD D
    • C07H19/213A61K31/665A61K31/675A61K31/7042A61K31/7052A61K31/7064A61K31/7068A61K31/7072A61K31/7076A61K31/708A61K49/00A61P1/16A61P3/00A61P3/04A61P3/06A61P3/10A61P9/10A61P31/12A61P33/00A61P35/00A61P43/00C07F9/6571C07F9/6574C07H19/10C07H19/11C07H19/20C07H19/207C07H19/00
    • C07H19/10C07F9/657154C07F9/657181C07F9/65742C07F9/65744C07H19/20C07H19/207
    • Prodrugs of formula (I), their uses, their intermediates, and their method of manufacture are described, wherein V is selected from the group consisting of -H, aralkyl, alicyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, 1-alkynyl, and -R ; or together V and Z are connected via 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, substituted with hydroxy, acyloxy, alkoxycarbonyloxy, or aryloxycarbonyloxy attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus; or together V and Z are connected via 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the oxygen attached to the phosphorus; or together V and W are connected via 3 carbon atoms to form an optionally substituted cyclic group containing 6 carbon atoms and substituted with one substituent selected from the group consisting of hydroxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy, and aryloxycarbonyloxy, attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus; W and W' are independently selected from the group consisting of -H, alkyl, aralkyl, alicyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, 1-alkynyl, and -R ; Z is selected from the group consisting of -CHR OH, -CHR OC(O)R , -CHR OC(S)R , -CHR OC(S)OR , -CHR OC(O)SR , -CHR OCO2R , -OR , -SR , -CHR N3, -CH2aryl, -CH(aryl)OH, -CH(CH=CR 2)OH, -CH(CCR )OH, -R , -NR 2, -OCOR , -OCO2R , -SCOR , -SCO2R , -NHCOR , -NHCO2R , -CH2NHaryl, -(CH2)p-OR , and -(CH2)p-SR ; R is an R or -H; R is selected from the group consisting of alkyl, aryl, aralkyl, and alicyclic; and R is selected from the group consisting of alkyl, aralkyl, and alicyclic; p is an integer from 2 to 3; with the provisos that a) V, Z, W, and W' are not all -H; and b) when z is -R , then at least one of V and W is not -H, or -R ; and M is selected from the group that attached to PO3 , P2O6 , or P3O9 is biologically active in vivo, and that is attached to the phosphorus in formula (I) via a carbon, oxygen, or nitrogen atom; and pharmaceutically acceptable prodrugs and salts thereof.
    • 描述了式(I)的前药,其用途,其中间体及其制备方法,其中V选自-H,芳烷基,脂环族,芳基,取代的芳基,杂芳基,取代的杂芳基,1-烯基 ,1-炔基和-R 9; 或一起V和Z通过3-5个原子连接形成环状基团,任选地含有1个被连接到磷上的氧原子连接到三个原子上的羟基,酰氧基,烷氧基羰基氧基或芳氧基羰基氧基的杂原子; 或一起V和Z通过3-5个原子连接以形成任选地含有1个杂原子的环状基团,其在β和γ位置处的芳基与连接到磷的氧融合; 或者一起V和W通过3个碳原子连接形成任选取代的含有6个碳原子的环状基团,并被一个选自羟基,酰氧基,烷氧基羰基氧基,烷硫基羰基氧基和芳氧基羰基氧基的一个取代基取代, 是从附着于磷的氧的三个原子; W和W'独立地选自-H,烷基,芳烷基,脂环族,芳基,取代的芳基,杂芳基,取代的杂芳基,1-烯基,1-炔基和-R 9。 Z选自-CHR 2 OH,-CHR 2 OC(O)R 3,-CHR 2 OC(S)R 3,-CHR 2 OC( S)OR 3,-CHR 2 OC(O)SR 3,-CHR 2 OCO 2 R 3,-OR 2,-SR 2,-CHR 2 N 3, -CH 2芳基,-CH(芳基)OH,-CH(CH = CR 2)OH,-CH(CCR 2)OH,-R 2,-NR 2,-OCOR 3 ,-OCO 2 R 3,-SCOR 3,-SCO 2 R 3,-NHCOR 2,-NHCO 2 R 3,-CH 2 NH芳基, - (CH 2)p -OR 2和 - (CH 2 )对 - SR <2>; R 2是R 3或-H; R 3选自烷基,芳基,芳烷基和脂环族; 并且R 9选自烷基,芳烷基和脂环族; p是2至3的整数; 条件是a)V,Z,W和W'不全为-H; 和b)当z是-R 2时,V和W中的至少一个不是-H或-R 9; 并且M选自附着于PO 3 2-,P 2 O 6 3-或P3O 9 4-的基团在体内具有生物活性,并且通过碳与式(I)中的磷连接, 氧或氮原子; 及其药学上可接受的前药及其盐。
    • 18. 发明申请
    • SYNTHESIS OF COMPOUNDS AND LIBRARIES OF COMPOUNDS
    • 化合物和化合物的合成
    • WO9948897B1
    • 2000-01-20
    • PCT/US9906233
    • 1999-03-22
    • HARVARD COLLEGE
    • VERDINE GREGORY LCHYTIL MILANDIDIUK MARY TMALINKY TIFFANY
    • C12N15/09C07B61/00C07C271/16C07C327/22C07D207/16C07D223/10C07D263/22C07F7/18C07F9/6574C07K1/00C07K1/04C40B40/02C40B40/04C40B40/16C40B50/00C40B50/06
    • C07K1/047C07B2200/11C07C271/16C07D207/16C07D223/10C07D263/22C07F9/65742C40B40/00
    • The present invention provides a system for the production of chemical compounds and libraries of compounds that are complex, stereochemically and regioselectively pure, and may mimic the structural or functional properties of a peptide. The invention provides methods for producing collections of peptidomimetic compounds which, in one preferred embodiment, comprises (1) providing two diversifiable monomers containing terminal reactive moieties; (2) reacting the monomers under conditions that allow for the control of stereochemistry as well as chemoselectivity; and (3) generating diversifiable isolable compounds or libraries of compounds. In another preferred embodiment, a collection of peptidomimetic compounds is provided by (1) providing at least one diversifiable monomer containing terminal reactive moieties; (2) reacting the monomer with a reagent under conditions that allow for the control of stereochemistry as well as chemoselectivity; and (3) generating diversifiable isolable compounds or libraries of compounds. In another broader aspect, the present invention provides for the synthesis of a collection of compounds comprising peptidomimetics and non-peptidomimetics alike having stereodiversity. This method involves the steps of (1) selecting desired synthetic precursors having a predefined stereochemical relationship; (2) reacting the synthetic precursors so that a compound having a specific stereochemistry is obtained; and (3) repeating these steps of selecting and reacting until a desired library of compounds having stereochemical diversity is obtained. In certain preferred embodiments, a library of compounds having only diversity of stererochemistry is provided. In certain other preferred embodiments, a library of compounds having structural diversity and stereochemical diversity is provided. The present invention also provides various chemical compounds useful in the inventive methods for production of complex peptidomimetic libraries. The peptidomimetic and stereodiverse compounds of the inventive method are useful for interactions with receptors in cells and may emulate the structure and functionality of peptides.
    • 本发明提供了一种用于制备复合物,立体化学和区域选择性纯化合物的化合物和文库的系统,并且可以模拟肽的结构或功能性质。 本发明提供了生产肽模拟化合物的方法,在一个优选的实施方案中,其包含(1)提供含有末端反应性部分的两种可分散的单体; (2)在允许控制立体化学和化学选择性的条件下使单体反应; 和(3)产生可分离的可分离化合物或化合物文库。 在另一个优选的实施方案中,肽模拟化合物的集合通过以下方式提供:(1)提供至少一种含有末端反应性部分的可分散单体; (2)在允许控制立体化学和化学选择性的条件下使单体与试剂反应; 和(3)产生可分离的可分离化合物或化合物文库。 在另一个更广泛的方面,本发明提供了合成包含拟肽的化合物和非肽模拟物的集合,其具有立体异构。 该方法包括以下步骤:(1)选择具有预定立体化学关系的所需合成前体; (2)使合成前体反应,得到具有特定立体化学的化合物; 和(3)重复这些选择和反应的步骤,直到获得具有立体化学多样性的所需化合物文库。 在某些优选实施方案中,提供了仅具有立体化学多样性的化合物文库。 在某些其它优选实施方案中,提供了具有结构多样性和立体化学多样性的化合物文库。 本发明还提供了用于生产复合肽模拟文库的本发明方法中的各种化合物。 本发明方法的拟肽和立体异构化合物可用于与细胞中的受体的相互作用,并且可以模拟肽的结构和功能。
    • 20. 发明申请
    • ANTIVIRAL AGENTS
    • 抗病毒剂
    • WO1995022330A1
    • 1995-08-24
    • PCT/AU1995000076
    • 1995-02-17
    • COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATIONMARCUCCIO, Sebastian, MarioHOLAN, GeorgeCOGHLAN, Phillip, AlbertJARVIS, Karen, ElizabethROBERTSON, Alan, DuncanTURNER, Kathleen, AnneWEIGOLD, Helmut
    • COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION
    • A61K31/52
    • C07D473/00A61K31/52C07F9/65616C07F9/65742
    • The invention relates to a method for the treatment and/or prophylaxis of a Hepadnaviridae associated infection which comprises administration of an effective amount of a compound of Formula (1), wherein R1 is hydrogen, halogen, hydroxy, azide, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryloxy, mercapto, optionally substituted alkylthio, optionally substituted amino, optionally substituted hydrazino or optionally substituted hydroxylamino; R2 is hydrogen, halogen, hydroxy, azide, optionally substituted alkoxy, optionally substituted aryloxy, mercapto, optionally substituted alkylthio or optionally substituted amino; R3 and R3' are the same or different and selected from hydrogen, optionally substituted alkyl, halogen, hydroxy, azide, optionally substituted alkoxy, optionally substituted aryloxy, mercapto, optionally substituted thio and optionally substituted amino; or R3 and R3' together form =O, =S, =NOH or =NOR, wherein R is optionally substituted alkyl; and R4, R5 and R6 are the same or different and selected from optionally substituted alkyl, optionally substituted aralkyl, halogen, hydroxy, azide, optionally substituted alkoxy, optionally substituted aryloxy, mercapto, optionally substituted alkylthio, optionally substituted amino, optionally substituted acyl, optionally substituted ester, cyano, carboxy and mono-, di- or tri- phosphate; two of R4, R5 and R6 are joined together to form a cyclic group; or R4, R5 and R6 are joined together to form a cyclic ortho ester group, salts thereof, pharmaceutically acceptable derivatives thereof, pro-drugs thereof, tautomers thereof and/or isomers thereof to a subject requiring said treatment and/or prophylaxis. The invention also relates to novel compounds of Formula (1), processes for their preparation and pharmaceutical or veterinary compositions containing them.
    • 本发明涉及一种治疗和/或预防肝炎病毒科相关感染的方法,其包括给予有效量的式(1)化合物,其中R 1是氢,卤素,羟基,叠氮化物,任选取代的烷基,任选地 取代的烷氧基,任选取代的芳氧基,巯基,任选取代的烷硫基,任选取代的氨基,任选取代的肼基或任选取代的羟基氨基; R 2是氢,卤素,羟基,叠氮化物,任选取代的烷氧基,任选取代的芳氧基,巯基,任选取代的烷硫基或任选取代的氨基; R 3和R 3'相同或不同,选自氢,任选取代的烷基,卤素,羟基,叠氮化物,任选取代的烷氧基,任选取代的芳氧基,巯基,任选取代的硫代和任选取代的氨基; 或R3和R3'一起形成= O,= S,= NOH或= NOR,其中R是任选取代的烷基; 卤素,羟基,叠氮化物,任选取代的烷氧基,任选取代的芳氧基,巯基,任选取代的烷硫基,任选取代的氨基,任选取代的酰基,任选取代的烷基, 任选取代的酯,氰基,羧基和一,二或三磷酸酯; R4,R5和R6中的两个连接在一起形成环状基团; 或R 4,R 5和R 6连接在一起以形成环状原酸酯基团,其盐,其药学上可接受的衍生物,其前药,其互变异构体和/或其异构体,用于需要所述治疗和/或预防的对象。 本发明还涉及式(1)的新化合物,其制备方法和含有它们的药物或兽药组合物。